TTK Healthcare Limited has announced that its board of directors will convene on January 22, 2026, to review and approve the company's unaudited financial results for the third quarter ended December 31, 2025. The meeting notification was issued on January 2, 2026, in compliance with regulatory requirements.

Board Meeting Details

The pharmaceutical company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda involves consideration and approval of the unaudited financial results for Q3FY26.

Trading Window Restrictions

TTK Healthcare Limited has implemented a trading window closure as part of its insider trading prevention measures. The restriction period extends from January 1, 2026, to January 24, 2026, covering both days inclusively. This measure affects all designated persons of the company and their immediate relatives, who have been specifically instructed not to trade in the company's shares during this period.

Regulatory Compliance Framework

The trading window closure follows the company's earlier communication dated December 26, 2025, which outlined the implementation of these restrictions. The measures align with the amended SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct designed to prevent insider trading activities.

The company has formally notified both the BSE Limited and National Stock Exchange of India Limited about the scheduled board meeting and associated trading restrictions. TTK Healthcare Limited trades on BSE with scrip code 507747 and on NSE with scrip code TTKHLTCARE.

TTK Healthcare Limited has announced the appointment of V Sundaresan as Additional Independent Director, following a board meeting held on December 22, 2025. The appointment, recommended by the company's Nomination and Remuneration Committee, is subject to shareholder approval through a special resolution via postal ballot.

Director Appointment Details

The board approved Sundaresan's appointment for a five-year term effective December 22, 2025. The appointment details are outlined below:

Professional Background and Expertise

Sundaresan brings extensive financial leadership experience to the board. He is a commerce graduate from the University of Madras and a Fellow Member of the Institute of Chartered Accountants of India (FCA). His professional journey spans nearly four decades in finance, accounts, audit, and regulatory compliance.

His career highlights include senior positions at prominent organizations:

• General Electric: Held senior financial positions
• Greaves Cotton Co.: Leadership role in finance operations
• BPL Refrigerators: Senior management position
• TTK Group: Nearly three decades of service, retiring as Chief Financial Officer of TTK Prestige Ltd. in October 2020
• Current Role: Partner with M/s Sowmya Sundaresan Co., Chartered Accountants

Key Professional Achievements

Sundaresan's expertise encompasses multiple areas of corporate finance and governance:

• Led enterprise transformation through ERP implementation and data-driven decision-making
• Played key roles in corporate restructuring, including demerger processes and overseas subsidiary establishment
• Established comprehensive audit frameworks and internal controls as an active Risk Management team member
• Developed profit-center accountability models to enhance operational efficiency
• Oversaw organization-wide transition to GST and new Accounting Standards
• Achieved significant improvements in working-capital cycles through analytics and fiscal discipline
• Maintained strong relationships with investors and analysts

Postal Ballot Process and Timeline

The board has approved conducting a postal ballot process through remote e-voting for shareholder approval of the appointment. M/s AK Jain Associates, represented by partners Balu Sridhar and Anil Kumar Jain, has been appointed as scrutinizer for the process.

Complete Calendar of Events

The board meeting commenced at 12:45 PM and concluded at 1:00 PM on December 22, 2025. The company has confirmed that Sundaresan is not disqualified or debarred from holding the office of Director pursuant to Section 164 of the Companies Act, 2013, or by virtue of any SEBI order or other authority. Sundaresan has no relationship with other directors and key managerial personnel of the company.